Tuesday 23 December 2014
CLSI M100-S23 Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Third Informational Supplement 2013
CLSI M100-S23 Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Third Informational Supplement 2013
********************************************
CLSI M100-S23 Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Third Informational Supplement 2013
OR
OR
Book Description
M100-S23 includes a dosage regimen for imipenem for Pseudomonas aeruginosa and new information for detection of inducible clindamycin resistance using the D-zone test or broth microdilution for Streptococcus pneumoniae. Also, the disk diffusion and minimal inhibitory concentration quality control frequency has been updated to include a new two-phase, 15-replicate (3 × 5 day) plan and flow chart. Expanded recommendations for testing fluoroquinolones and salmonella, and elimination breakpoints for beta-lactamase, other than oxacillin (cefoxitin), penicillin, and ceftaroline for staphylococci are included.
Jean B. Patel, PhD, D(ABMM), Deputy Director of the Office of Antimicrobial Resistance for the Centers for Disease Control and Prevention in Atlanta, Georgia, USA, and Vice-Chairholder of the CLSI Subcommittee on Antimicrobial Testing Standards, stated that, “There are a number of changes in this latest version of M100, but perhaps the most significant are the new ceftaroline interpretive criteria (or breakpoints) for several bacterial genera including Staphylococcus aureus, the new doxycycline, revised tetracycline breakpoints for Streptococcus pneumoniae, and the simplified Staphylococcus spp. table.”
This January, instantly access M100-S23 with CLSI’s new electronic product. eM100 is an interactive, searchable database for drug selection, interpretation, and QC procedures. Work more efficiently by providing the latest recommendations for detecting emerging resistance in an easy-to-use format. There is a version specifically designed for pharmacists to enhance the implementation of M100 information tailored to their organization.
The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing clinical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability. For additional information, visit the CLSI website at www.clsi.org or call 610.688.0100.
CLSI M100-S23 Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Third Informational Supplement 2013
Subscribe to:
Post Comments (Atom)
0 Responses to “CLSI M100-S23 Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Third Informational Supplement 2013”
Post a Comment